The pathobiologic features of carcinomas of type II pneumocytes. An immunocytologic study

Cancer. 1986 Mar 1;57(5):994-9. doi: 10.1002/1097-0142(19860301)57:5<994::aid-cncr2820570520>3.0.co;2-2.

Abstract

Adenocarcinomas of the lung without squamous differentiation or obvious mucus production from 51 patients were studied. Twenty-eight tumors (55%), when stained with rabbit anti-human surfactant apoprotein antiserum by the peroxidase-antiperoxidase method, demonstrated characteristic nuclear inclusions. Most of these tumors could be identified histochemically by the presence of eosinophilic, periodic acid-Schiff (PAS)-positive nuclear inclusions. In patients with apoprotein-immunoreactive tumors there were nine deaths due to tumor (32%) within 5 years of diagnosis. Eight of the nine deaths occurred in patients whose tumors exceeded 3 cm in diameter; an equal number of patients were smokers. The average age of patients with apoprotein-positive tumors was 67.3 years, a figure greater than that for patients with apoprotein-negative tumors (61.4 years). Five of the 23 patients with apoprotein-negative tumors died of their neoplasms; in two of the subjects the tumors exceeded 3 cm in diameter. In that no significant difference in survival was observed in patients with apoprotein-positive and apoprotein-negative tumors, it was concluded that subclassification of adenocarcinomas of the lung as apoprotein-positive, i.e., type II pneumocytic, or as apoprotein-negative, is of no clinical or prognostic significance. Nonetheless, peripheral tumors measuring less than 3 cm in size and showing neither squamous differentiation nor obvious mucus production should be recognized as a prognostically favorable group in comparison with other types of lung carcinomas.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Apoproteins / analysis
  • Carcinoma / mortality
  • Carcinoma / pathology*
  • Carcinoma / therapy
  • Cell Nucleus / analysis
  • Female
  • Histocytochemistry
  • Humans
  • Immunochemistry
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Mucins / analysis
  • Prognosis
  • Pulmonary Surfactant-Associated Proteins*
  • Pulmonary Surfactants / analysis
  • Smoking
  • Staining and Labeling

Substances

  • Apoproteins
  • Mucins
  • Pulmonary Surfactant-Associated Proteins
  • Pulmonary Surfactants
  • pulmonary surfactant apoprotein